Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of ...
The drug sorafenib, which is used to treat kidney and liver cancer, may be effective acute myeloid leukemia patients with specific gene mutations. Previous studies have shown that sorafenib is ...
ORLANDO, Fla.— Elderly patients with acute myeloid leukemia (AML) have a median overall survival of about 1 year when treated with currently available standard chemotherapy. Recently, phase 1/2 data ...
The importance of imatinib dose intensity in imatinib plus combination chemotherapy in newly diagnosed Ph+ ALL. Background: Elderly patients (pts) with acute myeloid leukemia (AML) may not be suitable ...
Prior to this past year, induction chemotherapy for patients with newly diagnosed acute myeloid leukemia (AML) had not changed appreciably for several decades. However, with the FDA approval of ...
Dasatinib plus SMO antagonist versus dasatinib alone for treating patients (pts) with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP): Design ...
The FLT3 gene contains instructions for a protein called FLT3, which helps white blood cells grow. A mutation in this gene encourages the growth of too many abnormal white blood cells. There are two ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results